Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > “Conference call to discuss “A” corporate update”….

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Apr 30, 2024 12:10pm

87 Views

Post# 36015014

RE:RE:RE:RE:“Conference call to discuss “A” corporate update”….

What I am saying is that negotiations between the candidate target company and interested acquiring companies are not for public consumption, as cited by the example of Alpine Immune Sciences and acquisition by Vertex for US$ 4.9 Billion, earlier this month.

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market